A Pilot Study of Differentiation Therapy in Multiple Myeloma Using Interleukin-6 and Interferon-a
- Determine the response rate in patients with recurrent multiple myeloma treated with
recombinant interferon alfa and recombinant interleukin-6.
- Determine the safety and optimal dose of this regimen in these patients.
- Determine the toxicity of this regimen in these patients.
- Determine the impact of this regimen on clonogenic growth of myeloma cells in serial in
OUTLINE: This is a pilot study.
Patients receive recombinant interferon alfa subcutaneously (SC) once daily. Beginning 1
month later, patients also receive recombinant interleukin-6 SC once daily. Treatment
continues for up to 6 months in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 27 patients will be accrued for this study.
Primary Purpose: Treatment
Carol A. Huff, MD
Sidney Kimmel Comprehensive Cancer Center
United States: Institutional Review Board
|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||Baltimore, Maryland 21231-2410|